Related references
Note: Only part of the references are listed.Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020)
Matteo Boattini et al.
JOURNAL OF CHEMOTHERAPY (2023)
An Observational Study of MDR Hospital-Acquired Infections and Antibiotic Use during COVID-19 Pandemic: A Call for Antimicrobial Stewardship Programs
Nour Shbaklo et al.
ANTIBIOTICS-BASEL (2022)
Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians
Luigi Principe et al.
PHARMACEUTICALS (2022)
Ten Years of KPC-Kp Bloodstream Infections Experience: Impact of Early Appropriate Empirical Therapy on Mortality
Silvia Corcione et al.
BIOMEDICINES (2022)
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales
Marco Falcone et al.
CLINICAL INFECTIOUS DISEASES (2021)
Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient
Paolo Gaibani et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2021)
Carbapenemase detection testing in the era of ceftazidime/avibactam-resistant KPC-producing Enterobacterales: A 2-year experience
Gabriele Bianco et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3
Giusy Tiseo et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Minireview on Novel Anti-infectious Treatment Options and Optimized Drug Regimens for Sepsis
Maya Hites
FRONTIERS IN MEDICINE (2021)
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals
Mariana Castanheira et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies
Stefano Di Bella et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy
Marianna Rossi et al.
EMERGING INFECTIOUS DISEASES (2021)
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China
P. Zhang et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization
P. Gaibani et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Ceftazidime-avibactam susceptible to resistant KPC-producing Enterobacterales bloodstream infections: an observational study
Marco Iannaccone et al.
JOURNAL OF CHEMOTHERAPY (2020)
Mobile genetic elements associated with carbapenemase genes in South American Enterobacterales
Jorge Anibal Reyes et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2020)
Fourier Transform Infrared Spectroscopy Is a New Option for Outbreak Investigation: a Retrospective Analysis of an Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae Outbreak in a Neonatal Intensive Care Unit
Nadya Rakovitsky et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay
Gabriele Bianco et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting-Focus on ICU Patients and Gram-Negative Strains
Chiara Adembri et al.
ANTIBIOTICS-BASEL (2020)
Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018
Alma Brolund et al.
EUROSURVEILLANCE (2019)
KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues
Alberto Antonelli et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Catherine L. Tooke et al.
JOURNAL OF MOLECULAR BIOLOGY (2019)
Phenotypic, Biochemical, and Genetic Analysis of KPC-41, a KPC-3 Variant Conferring Resistance to Ceftazidime-Avibactam and Exhibiting Reduced Carbapenemase Activity
Linda Mueller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Epidemiology of carbapenem-resistant Gram-negative infections globally
Adrian J. Brink
CURRENT OPINION IN INFECTIOUS DISEASES (2019)
Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae
William R. Wilson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient
Vasilios Athans et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study
Marie-Helene Nicolas-Chanoine et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)
Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship
Silvia Corcione et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2019)
In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment
Paolo Gaibani et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Validation of Scores and Proposal for Management
Angela Cano et al.
CLINICAL INFECTIOUS DISEASES (2018)
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
Latania K. Logan et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study
Hajo Grundmann et al.
LANCET INFECTIOUS DISEASES (2017)
In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections
Q. Wang et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2016)
Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop
Marisa L. Winkler et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding
Liang Chen et al.
TRENDS IN MICROBIOLOGY (2014)
Molecular Epidemiology of KPC-Producing Klebsiella pneumoniae Isolates in the United States: Clonal Expansion of Multilocus Sequence Type 258
Brandon Kitchel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Outbreak of Klebsiella pneumoniae producing a new carbapenern hydrolyzing class a β-lactamase, KPC-3, in a New York Medical Center
N Woodford et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Share Paper
